• GSK’s PD-1 inhibitor Jemperli approved in the UK pharmatimes
    June 08, 2021
    GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer.
  • FDA approves GSK’s Jemperli for endometrial cancer pharmaceutical-technology
    April 26, 2021
  • Evrysdi leads latest CHMP recommendations pharmatimes
    March 02, 2021
PharmaSources Customer Service